Bi‐specific antibodies (BiTE) directed against AML cells through either CD33 (Herrmann et al., 2018) or CD123 (Al‐Hussaini et al., 2016), can be brought into contact, and activate T cells, through CD3. This evidence concerns the gene CD33 and acute myeloid leukemia.